glimepiride Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihyperglycaemics	1300	93479-97-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: glimepiride diameprid glimax glimperide glirid	Molecular weight: 490.62 Formula: C24H34N4O5S CLOGP: 3.96 LIPINSKI: 0 HAC: 9 HDO: 3 TPSA: 124.68 ALOGS: -4.11 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
2	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.23 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.19 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 30, 1995	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	1677.85	10.78	846	38365	53503	46593348
Blood glucose increased	475.65	10.78	430	38781	71583	46575268
Lactic acidosis	326.54	10.78	252	38959	33657	46613194
Hypoglycaemic coma	293.40	10.78	102	39109	2472	46644379
Diabetes mellitus inadequate control	208.60	10.78	133	39078	13081	46633770
Blood glucose decreased	203.06	10.78	150	39061	18742	46628109
Glycosylated haemoglobin increased	193.20	10.78	118	39093	10758	46636093
Hypoglycaemic encephalopathy	145.24	10.78	36	39175	245	46646606
Myocardial infarction	136.82	10.78	272	38939	97256	46549595
Cardiac failure congestive	136.12	10.78	262	38949	91488	46555363
Acute kidney injury	136.00	10.78	471	38740	235384	46411467
Hyperglycaemia	117.33	10.78	146	39065	34925	46611926
Diabetes mellitus	96.04	10.78	160	39051	49905	46596946
Rheumatoid arthritis	89.55	10.78	45	39166	240170	46406681
Drug ineffective	86.76	10.78	287	38924	677551	45969300
Coronary artery disease	77.31	10.78	117	39094	33635	46613216
Diabetic metabolic decompensation	69.79	10.78	29	39182	1156	46645695
Diabetic ketoacidosis	67.71	10.78	80	39131	18130	46628721
Pancreatitis	67.61	10.78	127	39084	43500	46603351
Cerebral infarction	63.73	10.78	88	39123	23278	46623573
Hyperkalaemia	61.15	10.78	133	39078	50576	46596275
Maternal exposure during pregnancy	59.20	10.78	8	39203	102541	46544310
Blood glucose fluctuation	58.72	10.78	39	39172	4107	46642744
Exposure during pregnancy	56.74	10.78	11	39200	108201	46538650
Pancreatic carcinoma	50.90	10.78	43	39168	6514	46640337
Neuroglycopenia	49.86	10.78	11	39200	41	46646810
Decreased appetite	48.28	10.78	303	38908	193533	46453318
Pancreatitis acute	45.69	10.78	78	39133	24794	46622057
Drug intolerance	44.47	10.78	35	39176	147014	46499837
Altered state of consciousness	42.60	10.78	73	39138	23275	46623576
Joint swelling	42.57	10.78	46	39165	166027	46480824
Contraindicated product administered	42.17	10.78	8	39203	79939	46566912
Renal failure	42.11	10.78	198	39013	113396	46533455
MELAS syndrome	40.63	10.78	11	39200	110	46646741
Blood glucose abnormal	40.36	10.78	38	39173	6634	46640217
Off label use	39.21	10.78	175	39036	379666	46267185
Infusion related reaction	39.12	10.78	18	39193	101190	46545661
Sopor	38.84	10.78	64	39147	19764	46627087
Postprandial hypoglycaemia	37.42	10.78	9	39202	53	46646798
Synovitis	37.12	10.78	4	39207	61071	46585780
Systemic lupus erythematosus	35.51	10.78	6	39205	65174	46581677
Drug hypersensitivity	35.45	10.78	97	39114	243728	46403123
Metabolic acidosis	35.11	10.78	91	39120	38689	46608162
Bladder cancer	34.70	10.78	25	39186	3001	46643850
Euglycaemic diabetic ketoacidosis	33.57	10.78	21	39190	1995	46644856
Cold sweat	32.55	10.78	43	39168	10902	46635949
Renal impairment	32.35	10.78	136	39075	74236	46572615
Insulin C-peptide increased	31.48	10.78	8	39203	61	46646790
Ketoacidosis	30.83	10.78	26	39185	3929	46642922
Pain	29.78	10.78	257	38954	476691	46170160
Weight decreased	29.30	10.78	288	38923	210561	46436290
Ketosis	29.20	10.78	12	39199	465	46646386
Thrombotic cerebral infarction	27.64	10.78	8	39203	104	46646747
Blood creatinine increased	27.44	10.78	132	39079	76271	46570580
Shock hypoglycaemic	27.23	10.78	8	39203	110	46646741
Anuria	26.69	10.78	40	39171	11391	46635460
Pyelonephritis acute	25.88	10.78	24	39187	4110	46642741
Hypoparathyroidism	25.58	10.78	12	39199	641	46646210
Cerebrovascular accident	25.14	10.78	158	39053	100881	46545970
Hyperinsulinaemia	25.09	10.78	7	39204	79	46646772
Pemphigus	25.03	10.78	4	39207	45270	46601581
Hyperhidrosis	24.99	10.78	144	39067	89164	46557687
Dehydration	24.69	10.78	223	38988	159317	46487534
Blood urea increased	24.52	10.78	61	39150	25291	46621560
Diabetic retinopathy	24.10	10.78	18	39193	2284	46644567
Hypoglycaemic unconsciousness	24.06	10.78	12	39199	734	46646117
Cardiac failure	23.75	10.78	131	39080	79817	46567034
Cholelithiasis	23.71	10.78	79	39132	38602	46608249
Musculoskeletal stiffness	23.09	10.78	29	39182	97964	46548887
Drug level increased	22.94	10.78	49	39162	18392	46628459
Diarrhoea	22.59	10.78	622	38589	558980	46087871
Biopsy skin abnormal	21.97	10.78	7	39204	128	46646723
Injection site nodule	21.94	10.78	20	39191	3351	46643500
Diabetic neuropathy	21.81	10.78	21	39190	3768	46643083
Hepatic function abnormal	21.73	10.78	71	39140	34350	46612501
Abortion spontaneous	21.71	10.78	5	39206	43641	46603210
Medication error	21.56	10.78	66	39145	30845	46616006
Fatigue	21.54	10.78	371	38840	608326	46038525
Loss of consciousness	20.86	10.78	159	39052	108079	46538772
Fall	20.84	10.78	390	38821	328707	46318144
Depressed level of consciousness	20.69	10.78	87	39124	47482	46599369
Urogenital haemorrhage	20.68	10.78	7	39204	156	46646695
Muscle discomfort	20.59	10.78	6	39205	80	46646771
Completed suicide	20.48	10.78	59	39152	145861	46500990
Nasopharyngitis	20.37	10.78	64	39147	153934	46492917
Glossodynia	20.32	10.78	6	39205	44367	46602484
Hypersensitivity	20.21	10.78	62	39149	150259	46496592
Therapeutic product effect decreased	19.93	10.78	24	39187	82577	46564274
Hypothermia	19.53	10.78	36	39175	12147	46634704
Drug interaction	19.43	10.78	258	38953	202836	46444015
Headache	19.43	10.78	284	38927	478068	46168783
Differential white blood cell count abnormal	19.41	10.78	10	39201	655	46646196
Neutropenia	19.30	10.78	59	39152	143145	46503706
Drug abuse	19.27	10.78	15	39196	63393	46583458
Blood insulin increased	18.82	10.78	6	39205	110	46646741
Urine ketone body present	18.61	10.78	15	39196	2127	46644724
Sinusitis	18.55	10.78	52	39159	129716	46517135
Treatment failure	18.53	10.78	31	39180	93056	46553795
Diabetic complication	18.37	10.78	11	39200	966	46645885
Product use in unapproved indication	18.03	10.78	30	39181	90243	46556608
Anti-insulin antibody increased	17.88	10.78	5	39206	57	46646794
Anaemia vitamin B12 deficiency	17.85	10.78	8	39203	384	46646467
Dermatitis exfoliative	17.84	10.78	23	39188	5693	46641158
Bradypnoea	17.79	10.78	17	39194	3022	46643829
Rhabdomyolysis	17.72	10.78	76	39135	41833	46605018
Acute myocardial infarction	17.65	10.78	63	39148	31861	46614990
Hyporesponsive to stimuli	16.96	10.78	10	39201	854	46645997
Alopecia	16.60	10.78	75	39136	162339	46484512
Glycosylated haemoglobin abnormal	16.56	10.78	5	39206	76	46646775
Foetal exposure during pregnancy	16.37	10.78	3	39208	30744	46616107
Heart injury	15.98	10.78	11	39200	1228	46645623
Arthralgia	15.65	10.78	214	38997	364389	46282462
Oliguria	15.47	10.78	27	39184	8732	46638119
Oedema peripheral	15.31	10.78	203	39008	159503	46487348
Migraine	15.20	10.78	22	39189	70004	46576847
Pancreatic carcinoma metastatic	15.11	10.78	14	39197	2394	46644457
Hypomagnesaemia	15.10	10.78	47	39164	22163	46624688
Pemphigoid	14.87	10.78	21	39190	5670	46641181
Restlessness	14.65	10.78	51	39160	25473	46621378
Hepatic steatosis	14.64	10.78	49	39162	23993	46622858
Transient ischaemic attack	14.53	10.78	63	39148	34840	46612011
Musculoskeletal pain	14.29	10.78	23	39188	70105	46576746
Retinal haemorrhage	14.23	10.78	19	39192	4864	46641987
Product use issue	14.22	10.78	37	39174	94607	46552244
Mixed anxiety and depressive disorder	14.08	10.78	5	39206	129	46646722
Myocardial ischaemia	13.75	10.78	32	39179	12717	46634134
Pregnancy	13.71	10.78	3	39208	27134	46619717
Blood potassium increased	13.53	10.78	38	39173	16929	46629922
Febrile neutropenia	13.46	10.78	38	39173	94589	46552262
Arteriosclerosis	13.44	10.78	27	39184	9706	46637145
Asthenia	13.41	10.78	349	38862	310726	46336125
Carotid arteriosclerosis	13.35	10.78	9	39202	971	46645880
Hyperthyroidism	13.30	10.78	30	39181	11681	46635170
Liver disorder	13.11	10.78	64	39147	37182	46609669
Blood creatine phosphokinase increased	13.07	10.78	52	39159	27672	46619179
Azotaemia	12.79	10.78	17	39194	4334	46642517
Gastroenteritis	12.71	10.78	47	39164	24172	46622679
Phobia	12.51	10.78	6	39205	337	46646514
Pylorus dilatation	12.43	10.78	3	39208	18	46646833
Dry eye	12.33	10.78	5	39206	30317	46616534
Anaphylactic reaction	12.21	10.78	16	39195	53096	46593755
Hyperventilation	12.11	10.78	19	39192	5628	46641223
Macular oedema	12.02	10.78	16	39195	4085	46642766
Capillary leak syndrome	11.85	10.78	11	39200	1886	46644965
Infection	11.75	10.78	65	39146	133527	46513324
Compartment syndrome	11.36	10.78	11	39200	1988	46644863
Pulse abnormal	11.18	10.78	10	39201	1634	46645217
Cholecystitis	11.14	10.78	32	39179	14434	46632417
Blood triglycerides increased	11.02	10.78	28	39183	11755	46635096
Renal disorder	10.98	10.78	48	39163	26638	46620213
Angina pectoris	10.89	10.78	48	39163	26727	46620124
Lipase increased	10.86	10.78	23	39188	8580	46638271
Type 2 diabetes mellitus	10.79	10.78	39	39172	19836	46627015

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	1400.06	10.85	879	41426	50102	29860071
Blood glucose increased	329.91	10.85	420	41885	61110	29849063
Hypoglycaemic coma	307.78	10.85	118	42187	2213	29907960
Lactic acidosis	246.02	10.85	260	42045	30953	29879220
Diabetes mellitus inadequate control	223.07	10.85	167	42138	12595	29897578
Glycosylated haemoglobin increased	202.04	10.85	140	42165	9351	29900822
Myocardial infarction	179.23	10.85	483	41822	125142	29785031
Coronary artery disease	158.97	10.85	266	42039	49446	29860727
Cardiac failure congestive	143.56	10.85	347	41958	84060	29826113
Cerebral infarction	139.47	10.85	179	42126	26194	29883979
Bladder cancer	118.08	10.85	100	42205	9002	29901171
Pancreatitis	104.47	10.85	186	42119	36304	29873869
Blood glucose decreased	99.69	10.85	107	42198	12946	29897227
Hyperglycaemia	88.90	10.85	170	42135	35030	29875143
Diabetes mellitus	83.06	10.85	183	42122	41682	29868491
Pancreatic carcinoma	79.62	10.85	75	42230	7762	29902411
Drug abuse	74.60	10.85	13	42292	82059	29828114
Pancreatitis acute	73.55	10.85	131	42174	25564	29884609
Off label use	67.14	10.85	159	42146	249131	29661042
Hyperkalaemia	60.59	10.85	218	42087	65792	29844381
Hypoglycaemic encephalopathy	58.24	10.85	19	42286	216	29909957
Diabetic ketoacidosis	57.09	10.85	90	42215	15896	29894277
Interstitial lung disease	56.26	10.85	200	42105	59997	29850176
Cerebrovascular accident	56.01	10.85	250	42055	83227	29826946
Toxicity to various agents	53.44	10.85	106	42199	177077	29733096
Hepatic function abnormal	51.51	10.85	153	42152	41792	29868381
Product use in unapproved indication	51.18	10.85	20	42285	73673	29836500
Acute kidney injury	50.33	10.85	599	41706	273243	29636930
Altered state of consciousness	46.38	10.85	93	42212	19826	29890347
Neutropenia	45.95	10.85	69	42236	128471	29781702
Acute myocardial infarction	42.88	10.85	168	42137	52771	29857402
Blood lactic acid	42.28	10.85	17	42288	363	29909810
Heart injury	36.88	10.85	24	42281	1442	29908731
Pemphigoid	36.52	10.85	49	42256	7479	29902694
Drug ineffective	35.08	10.85	310	41995	340077	29570096
Gastric cancer	33.33	10.85	38	42267	4912	29905261
Diabetic nephropathy	31.62	10.85	24	42281	1845	29908328
Death	31.09	10.85	339	41966	356944	29553229
Treatment failure	30.41	10.85	6	42299	34673	29875500
Decreased appetite	30.15	10.85	334	41971	149576	29760597
Bladder transitional cell carcinoma	29.87	10.85	26	42279	2427	29907746
Urine ketone body present	29.58	10.85	18	42287	961	29909212
Myocardial ischaemia	29.15	10.85	71	42234	17246	29892927
Renal impairment	29.02	10.85	211	42094	83973	29826200
Diabetic metabolic decompensation	28.97	10.85	20	42285	1326	29908847
Dyslalia	28.31	10.85	14	42291	494	29909679
Febrile neutropenia	27.87	10.85	69	42236	106624	29803549
Completed suicide	27.87	10.85	62	42243	99430	29810743
Blood glucose abnormal	25.15	10.85	34	42271	5225	29904948
Hypoglycaemic unconsciousness	24.65	10.85	15	42290	801	29909372
Liver disorder	24.60	10.85	95	42210	29627	29880546
Blindness transient	24.33	10.85	21	42284	1938	29908235
Diabetic retinopathy	24.29	10.85	20	42285	1730	29908443
Pancreatic carcinoma metastatic	23.70	10.85	26	42279	3221	29906952
Lipase increased	23.25	10.85	43	42262	8633	29901540
Shock	22.24	10.85	77	42228	22782	29887391
Ischaemic cardiomyopathy	21.85	10.85	35	42270	6262	29903911
Cardiac failure	21.65	10.85	196	42109	83222	29826951
Latent autoimmune diabetes in adults	21.09	10.85	6	42299	41	29910132
Coronary artery stenosis	20.69	10.85	42	42263	9028	29901145
Glycosylated haemoglobin decreased	20.25	10.85	10	42295	352	29909821
Amylase increased	19.63	10.85	32	42273	5809	29904364
Blood glucose fluctuation	19.57	10.85	25	42280	3636	29906537
Lacunar infarction	19.21	10.85	23	42282	3132	29907041
Joint swelling	18.98	10.85	23	42282	46923	29863250
Angina pectoris	18.71	10.85	87	42218	29431	29880742
Drug resistance	18.70	10.85	3	42302	20130	29890043
Product commingling	18.42	10.85	5	42300	28	29910145
Brain stem infarction	18.28	10.85	15	42290	1291	29908882
Rheumatoid arthritis	17.94	10.85	19	42286	41178	29868995
Haemorrhagic cerebral infarction	17.68	10.85	12	42293	774	29909399
Pyrexia	17.42	10.85	302	42003	294187	29615986
Lower respiratory tract infection	17.33	10.85	8	42297	26706	29883467
Cytomegalovirus infection	17.14	10.85	6	42299	23668	29886505
Mucosal inflammation	17.07	10.85	11	42294	30483	29879690
Hypothermia	16.93	10.85	40	42265	9527	29900646
Arteriosclerosis	16.74	10.85	43	42262	10790	29899383
Albumin urine present	16.69	10.85	9	42296	381	29909792
Blood lactate dehydrogenase increased	16.36	10.85	65	42240	20536	29889637
Aggression	16.09	10.85	17	42288	36890	29873283
Thrombotic cerebral infarction	15.80	10.85	8	42297	297	29909876
Coronary artery bypass	15.64	10.85	27	42278	5135	29905038
Coronary arterial stent insertion	15.51	10.85	24	42281	4170	29906003
Nephrogenic anaemia	15.39	10.85	17	42288	2122	29908051
Headache	15.38	10.85	174	42131	182132	29728041
Infusion related reaction	15.23	10.85	21	42284	40543	29869630
Carotid artery stenosis	14.97	10.85	25	42280	4629	29905544
Cardiac disorder	14.91	10.85	102	42203	39791	29870382
Diabetic gangrene	14.79	10.85	7	42298	224	29909949
Hepatocellular carcinoma	14.70	10.85	38	42267	9572	29900601
Blood urea increased	14.69	10.85	85	42220	31296	29878877
Leukopenia	14.13	10.85	37	42268	56122	29854051
Weight decreased	14.09	10.85	295	42010	150626	29759547
Blood creatinine increased	13.78	10.85	193	42112	91182	29818991
Diabetic neuropathy	13.73	10.85	22	42283	3937	29906236
Renal failure	13.69	10.85	257	42048	128709	29781464
Insulin resistance	13.65	10.85	9	42296	553	29909620
Transient ischaemic attack	13.64	10.85	71	42234	25129	29885044
Anxiety	13.58	10.85	73	42232	89798	29820375
Metabolic acidosis	13.53	10.85	95	42210	37366	29872807
Acute coronary syndrome	13.44	10.85	46	42259	13527	29896646
Gastric adenoma	13.40	10.85	3	42302	6	29910167
Anti-insulin antibody increased	13.28	10.85	5	42300	89	29910084
Hyperglycaemic hyperosmolar nonketotic syndrome	13.25	10.85	11	42294	963	29909210
Symmetrical drug-related intertriginous and flexural exanthema	13.22	10.85	6	42299	174	29909999
Ketonuria	13.06	10.85	9	42296	595	29909578
Colon cancer	12.70	10.85	33	42272	8339	29901834
Blood triglycerides increased	12.59	10.85	46	42259	13971	29896202
Pancreatitis chronic	12.53	10.85	14	42291	1770	29908403
Respiratory tract haemorrhage	12.43	10.85	10	42295	837	29909336
Thrombocytopenia	12.27	10.85	129	42176	136915	29773258
Bile duct cancer	12.21	10.85	9	42296	662	29909511
Blood lactic acid increased	12.13	10.85	26	42279	5804	29904369
Hyperuricaemia	12.11	10.85	30	42275	7364	29902809
Hospitalisation	12.08	10.85	28	42277	44291	29865882
Arthralgia	12.08	10.85	128	42177	135663	29774510
Adenocarcinoma pancreas	11.78	10.85	12	42293	1366	29908807
Bladder neoplasm	11.74	10.85	11	42294	1130	29909043
Respiratory alkalosis	11.66	10.85	12	42293	1382	29908791
Cardiovascular disorder	11.63	10.85	38	42267	10914	29899259
Peritonitis	11.57	10.85	8	42297	21367	29888806
Angina unstable	11.57	10.85	41	42264	12269	29897904
Pain	11.52	10.85	173	42132	172468	29737705
Fasting	11.51	10.85	3	42302	14	29910159
Pancreatic neuroendocrine tumour	11.46	10.85	6	42299	239	29909934
Suicidal ideation	11.38	10.85	21	42284	36093	29874080
Retinal aneurysm	11.32	10.85	5	42300	136	29910037
Hepatic cancer	11.18	10.85	27	42278	6521	29903652
Hypersensitivity	11.15	10.85	39	42266	53989	29856184
Product use issue	11.06	10.85	31	42274	45985	29864188
Oedema peripheral	10.91	10.85	210	42095	105622	29804551
Hemiplegia	10.88	10.85	27	42278	6634	29903539

Pharmacologic Action:

Source	Code	Description
ATC	A10BB12	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sulfonylureas
ATC	A10BD04	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
ATC	A10BD06	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs
FDA CS	M0020795	Sulfonylurea Compounds
FDA EPC	N0000175608	Sulfonylurea
CHEBI has role	CHEBI:35526	hypoglycemic drug
CHEBI has role	CHEBI:90415	insulin secretagogues
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D007004	Hypoglycemic Agents
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Treatment Refractory Type 2 Diabetes Mellitus	indication
Alcoholism	contraindication	7200002
Weight gain finding	contraindication	8943002
Asthenia	contraindication	13791008
Pulmonary edema	contraindication	19242006	DOID:11396
Myocardial infarction	contraindication	22298006	DOID:5844
Macular retinal edema	contraindication	37231002	DOID:4449
Infectious disease	contraindication	40733004
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Hepatic porphyria	contraindication	55056006	DOID:3133
Hemolytic anemia	contraindication	61261009	DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia	contraindication	62403005
Osteoporosis	contraindication	64859006	DOID:11476
Hypopituitarism	contraindication	74728003	DOID:9406
Kidney disease	contraindication	90708001	DOID:557
Fracture of bone	contraindication	125605004
Autonomic dysreflexia	contraindication	129618003
Liver function tests abnormal	contraindication	166603001
Angina pectoris	contraindication	194828000
Decompensated cardiac failure	contraindication	195111005
Cerebrovascular accident	contraindication	230690007
Disease of liver	contraindication	235856003	DOID:409
Drug-induced hepatitis	contraindication	235876009
Hypoglycemic disorder	contraindication	237630007
Edema	contraindication	267038008
Osteopenia	contraindication	312894000
Primary adrenocortical insufficiency	contraindication	373662000
Fever	contraindication	386661006
Surgical procedure	contraindication	387713003
Malignant tumor of urinary bladder	contraindication	399326009	DOID:11054
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Traumatic injury	contraindication	417746004
Fever greater than 100.4 Fahrenheit	contraindication	426000000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.31	acidic
pKa2	13.98	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sulfonylurea receptor 1, Kir6.2	Ion channel	Q09428 Q14654	ABCC8_HUMAN KCJ11_HUMAN	BLOCKER	Ki	9.24		WOMBAT-PK	CHEMBL
Sulfonylurea receptor 2, Kir6.2	Ion channel	O60706 Q14654	ABCC9_HUMAN KCJ11_HUMAN	BLOCKER	Ki	7.98		WOMBAT-PK

External reference:

ID	Source
4020945	VUID
N0000148425	NUI
D00593	KEGG_DRUG
4020945	VANDF
C0061323	UMLSCUI
CHEBI:5383	CHEBI
GMR	PDB_CHEM_ID
CHEMBL1481	ChEMBL_ID
DB00222	DRUGBANK_ID
C057619	MESH_SUPPLEMENTAL_RECORD_UI
6820	IUPHAR_LIGAND_ID
5718	INN_ID
6KY687524K	UNII
3476	PUBCHEM_CID
25789	RXNORM
4782	MMSL
72042	MMSL
d03864	MMSL
005624	NDDF
109079009	SNOMEDCT_US
386966003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
AMARYL	HUMAN PRESCRIPTION DRUG LABEL	1	0039-0221	TABLET	1 mg	ORAL	NDA	26 sections
AMARYL	HUMAN PRESCRIPTION DRUG LABEL	1	0039-0222	TABLET	2 mg	ORAL	NDA	26 sections
AMARYL	HUMAN PRESCRIPTION DRUG LABEL	1	0039-0223	TABLET	4 mg	ORAL	NDA	26 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-6564	TABLET	1 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-6565	TABLET	2 mg	ORAL	ANDA	26 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-6566	TABLET	4 mg	ORAL	ANDA	26 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8332	TABLET	1 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8333	TABLET	2 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8334	TABLET	4 mg	ORAL	ANDA	25 sections
Pioglitazone hydrochloride and glimepiride	HUMAN PRESCRIPTION DRUG LABEL	2	0781-5634	TABLET	2 mg	ORAL	ANDA	28 sections
Pioglitazone hydrochloride and glimepiride	HUMAN PRESCRIPTION DRUG LABEL	2	0781-5635	TABLET	4 mg	ORAL	ANDA	28 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-217	TABLET	2 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-219	TABLET	4 mg	ORAL	ANDA	25 sections
Glimepiride	Human Prescription Drug Label	1	16571-773	TABLET	1 mg	ORAL	ANDA	25 sections
Glimepiride	Human Prescription Drug Label	1	16571-774	TABLET	2 mg	ORAL	ANDA	25 sections
Glimepiride	Human Prescription Drug Label	1	16571-775	TABLET	4 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-001	TABLET	1 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-002	TABLET	2 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-003	TABLET	4 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-746	TABLET	2 mg	ORAL	ANDA	20 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-747	TABLET	4 mg	ORAL	ANDA	20 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-993	TABLET	1 mg	ORAL	ANDA	20 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	33261-831	TABLET	2 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	33261-892	TABLET	4 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	33261-961	TABLET	1 mg	ORAL	ANDA	26 sections
GLIMEPIRIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42549-498	TABLET	4 mg	ORAL	ANDA	28 sections
GLIMEPIRIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42549-499	TABLET	2 mg	ORAL	ANDA	24 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	42571-100	TABLET	1 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	42571-101	TABLET	2 mg	ORAL	ANDA	25 sections
Glimepiride	HUMAN PRESCRIPTION DRUG LABEL	1	42571-102	TABLET	3 mg	ORAL	ANDA	25 sections